Talactoferrin alfa

Drug Profile

Talactoferrin alfa

Alternative Names: Apolactoferrin; Lactoferrin - Agennix; rhLF; Talactoferrin; TLF - Agennix

Latest Information Update: 05 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agennix
  • Developer Agennix; Agennix AG
  • Class Anti-inflammatories; Antineoplastics; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Renal cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic contact dermatitis; Asthma; Bacterial infections; Diabetic foot ulcer; Dry eyes; Gastritis; Mucositis; Non-small cell lung cancer; Nosocomial infections; Psoriasis; Renal cancer; Sepsis

Most Recent Events

  • 06 Aug 2012 Safety and efficacy data from the FORTIS-M phase III trial (monotherapy, third-line therapy) in Non-small cell lung cancer released by Agennix AG
  • 02 Feb 2012 Suspended - Phase-II/III for Sepsis in Canada (PO)
  • 02 Feb 2012 Suspended - Phase-II/III for Sepsis in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top